Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-61.43M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -44.34% |
| Return on Assets (Trailing 12 Months) | -36.73% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.18 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.65 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.50 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.39 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 27.08M |
| Free Float | -- |
| Market Capitalization | $152.71M |
| Average Volume (Last 20 Days) | 3.35M |
| Beta (Past 60 Months) | 2.00 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |